Skip to main content
. 2010 Jul 14;31(9):1567–1575. doi: 10.1093/carcin/bgq147

Fig. 2.

Fig. 2.

Expression of EZH2 and RUNX3 in normal human colon and in CRC specimens using immunohistochemistry. (A) Expression pattern of EZH2 in normal human colon. (B) Expression pattern of RUNX3 in normal human colon. (C) Positive nuclear EZH2 staining in CRC. (D) Positive RUNX3 expression in CRC. (E) Overexpression of EZH2 in cancer tissue. (F) Negative expression of RUNX3 in cancer tissue. (G) EZH2 shows negative staining in 9 (12.5%), positive staining in 9 (12.5%) and is overexpressed in 54 (75%) of CRC patients. RUNX3 is not expressed in 46 (64%) and exhibits positive nuclear or cytoplasmatic staining in 23 (36%) of CRC patients.